To demonstrate how cancer-specific predictions can be used to identify novel efficacious drug combinations, we performed an example analysis in EGFR wild-type lung cancer (which is the cancer subtype with the most available cell lines in CTRPv2) aimed at identifying efficacious two-drug combinations with navitoclax, a BCL inhibitor currently in phase I/II clinical trials for lung cancer in various combinations. This evidence concerns the gene EGFR and lung carcinoma.